Albert-Ludwigs-Universität Freiburg

University / College


Location: Freiburg i. Br., Germany (DE) DE

ISNI: -

ROR: https://ror.org/0245cg223

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma (2022) Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Salié H, Vollmer L, et al. Journal article Synthesis and Characterization of Stable Iron Pentacarbonyl Radical Cation Salts (2022) Rall JM, Schorpp M, Keilwerth M, Maylander M, Friedmann C, Daub M, Richert S, et al. Journal article The COVID-19 temptation?: Sino-Gulf relations and autocratic linkages in times of a global pandemic (2022) Demmelhuber T, Gurol J, Zumbrägel T Authored book Early and Strong Leptin Reduction Is Predictive for Long-Term Weight Loss during High-Protein, Low-Glycaemic Meal Replacement—A Subanalysis of the Randomised-Controlled ACOORH Trial (2022) Kempf K, Roehling M, Banzer W, Braumann KM, Halle M, Schaller N, Mccarthy D, et al. Journal article LONG-TERM SAFETY OF CANAKINUMAB IN PATIENTS WITH AUTOINFLAMMATORY DISEASES - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Kuemmerle-Deschner JB, Henes J, Kortus-Goetze B, Kallinich T, Oommen P, Rech J, Krickau T, et al. Conference contribution LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER (FMF) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Henes J, Kuemmerle-Deschner JB, Krickau T, Kallinich T, Dressler F, Horneff G, Meier F, et al. Conference contribution SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TITAIN TRIAL (2022) Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, Mendelson M, et al. Conference contribution Web-based mindfulness and skills-based distress reduction for patients with cancer: study protocol of the multicentre, randomised, controlled confirmatory intervention trial Reduct (2022) Baeuerle A, Martus P, Erim Y, Schug C, Heinen J, Krakowczyk JB, Steinbach J, et al. Journal article Uromodulin and its association with urinary metabolites: the German Chronic Kidney Disease Study (2022) Bächle H, Sekula P, Schlosser P, Steinbrenner I, Cheng Y, Kotsis F, Meiselbach H, et al. Journal article Genome-wide studies reveal factors associated with circulating uromodulin and its relationships to complex diseases (2022) Li Y, Cheng Y, Consolato F, Schiano G, Chong MR, Pietzner M, Nguyen NQH, et al. Journal article